Bachem Holding AG Class B (CH:BANB)
:BANB
Want to see CH:BANB full AI Analyst Report?
BANB Stock Chart & Stats
CHF70.15
CHF0.05(0.09%)
At close: 4:00 PM EST
CHF70.15
CHF0.05(0.09%)
Day’s Range― - ―
52-Week RangeCHF48.52 - CHF83.25
Previous CloseN/A
Volume38.68K
Average Volume (3M)109.83K
Market Cap
CHF5.32B
Enterprise ValueCHF5.79B
Total Cash (Recent Filing)CHF30.99M
Total Debt (Recent Filing)CHF57.39M
Price to Earnings (P/E)34.2
Beta0.74
Next Earnings
Jul 30, 2026EPS Estimate
0.73Next Dividend Ex-DateN/A
Dividend Yield1.43%
Share Statistics
EPS (TTM)1.99
Shares Outstanding75,000,000
10 Day Avg. Volume97,857
30 Day Avg. Volume109,830
Financial Highlights & Ratios
PEG Ratio1.27
Price to Book (P/B)3.08
Price to Sales (P/S)6.46
P/FCF Ratio-93.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF84.20Price Target Upside20.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)2.41
Revenue Forecast (FY)CHF951.50M
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet And Low LeverageBachem’s extremely low debt-to-equity and a growing equity base provide durable financial flexibility, reducing refinancing and interest-rate risks. This conservative financing supports long-term investment in capacity and R&D without forcing asset sales or dilutive capital raises, strengthening resilience.
Recurring Commercial-supply And CDMO Business ModelThe mix of long-term commercial supply contracts plus development-to-commercial conversion creates recurring revenue and a visible project pipeline. Successful transitions from R&D to commercial manufacturing convert one-time fees into durable, high-duration supply agreements, supporting revenue persistency.
Solid Profitability And Steady Revenue GrowthConsistent top-line expansion and healthy ~21% net margins indicate a resilient operating model with pricing power in peptide APIs and CDMO services. Steady growth and entrenched margins provide a durable earnings base that supports reinvestment and long-term shareholder returns.
Bears Say
Persistent Negative Free Cash FlowDespite positive operating cash flow in absolute terms, repeated negative free cash flow signals heavy capex or working-capital demands. Over time this can constrain funding for growth, dividends or debt reduction unless operational conversion improves or external financing increases.
Uneven Cash Conversion Of EarningsInconsistent conversion of accrual earnings into cash creates forecasting and reinvestment uncertainty. For a manufacturing/CDMO business, volatile working capital or timing of milestone receipts can strain liquidity and reduce the predictability of free cash flow over multi-quarter horizons.
Revenue Timing Risk From Customer PipelinesRevenue growth depends materially on customers advancing drug programs from development to commercialization. Delays, clinical failures, or reprioritization at customers can postpone or reduce expected commercial supply contracts, making top-line timing and scale partly contingent on external drug-development outcomes.
Bachem Holding AG News
BANB FAQ
What was Bachem Holding AG Class B’s price range in the past 12 months?
Bachem Holding AG Class B lowest stock price was CHF48.52 and its highest was CHF83.25 in the past 12 months.
What is Bachem Holding AG Class B’s market cap?
Bachem Holding AG Class B’s market cap is CHF5.32B.
When is Bachem Holding AG Class B’s upcoming earnings report date?
Bachem Holding AG Class B’s upcoming earnings report date is Jul 30, 2026 which is in 56 days.
How were Bachem Holding AG Class B’s earnings last quarter?
Bachem Holding AG Class B released its earnings results on Mar 12, 2026. The company reported CHF1.32 earnings per share for the quarter, beating the consensus estimate of CHF0.923 by CHF0.397.
Is Bachem Holding AG Class B overvalued?
According to Wall Street analysts Bachem Holding AG Class B’s price is currently Undervalued.
Does Bachem Holding AG Class B pay dividends?
Bachem Holding AG Class B pays a Annually dividend of CHF0.85 which represents an annual dividend yield of 1.43%. See more information on Bachem Holding AG Class B dividends here
What is Bachem Holding AG Class B’s EPS estimate?
Bachem Holding AG Class B’s EPS estimate is 0.73.
How many shares outstanding does Bachem Holding AG Class B have?
Bachem Holding AG Class B has 75,000,000 shares outstanding.
What happened to Bachem Holding AG Class B’s price movement after its last earnings report?
Bachem Holding AG Class B reported an EPS of CHF1.32 in its last earnings report, beating expectations of CHF0.923. Following the earnings report the stock price went up 7.734%.
Which hedge fund is a major shareholder of Bachem Holding AG Class B?
Currently, no hedge funds are holding shares in CH:BANB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bachem Holding AG Class B
Bachem Holding AG provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. The company engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). It also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services. The company was founded in 1971 and is headquartered in Bubendorf, Switzerland. Bachem Holding AG operates as a subsidiary of Ingro Finanz AG.
BANB Stock 12 Month Forecast
Average Price Target
CHF84.20
▲(20.03% Upside)
Technical Analysis
Lonza Group Ltd
―
Siegfried Holding AG
―
Ypsomed Holding AG
―
PolyPeptide Group AG
―
Galenica AG
―
Options Prices
Currently, No data available
---